Compounds that require bioavailability enhancement to achieve target absorption are increasingly common in current pipelines.
Accordingly, these compounds are paired with various technologies to enable progression.
This presentation will focus on the rationale for selecting these enabling technologies based on compound’s physical properties (e.g., Tm, Tg, LogP) and product specifications (e.g., dose, pharmacokinetics, permeability).
Case studies will be presented that illustrate this process of technology and formulation selection based on the above descriptors.
See the webinar here: